Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-03-15
2010-12-21
Wilson, James O (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S241000, C514S262100, C514S260100, C514S266220, C514S269000, C544S209000, C544S255000, C544S256000, C544S310000, C544S284000, C544S278000
Reexamination Certificate
active
07855194
ABSTRACT:
This invention is concerned with compounds of the formulawherein A, R1to R5and G are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are associated with the modulation of SST receptors subtype 5.
REFERENCES:
patent: 3931181 (1976-01-01), Kompis et al.
patent: 3956495 (1976-05-01), Lacefield
patent: 4255429 (1981-03-01), Werner
patent: 4309541 (1982-01-01), Werner
patent: 4499092 (1985-02-01), Hallot et al.
patent: 6140353 (2000-10-01), Ackermann et al.
patent: 6159982 (2000-12-01), Bosmans et al.
patent: 2121 031 (1972-11-01), None
patent: 243 59 34 (1975-02-01), None
patent: 0009 465 (1980-04-01), None
patent: 488 861 (1992-06-01), None
patent: 0921 116 (1999-06-01), None
patent: 1 571 146 (2005-09-01), None
patent: 2514 765 (1983-04-01), None
patent: WO 92/01687 (1992-02-01), None
patent: WO 00/35 858 (2000-06-01), None
patent: WO 01/32 633 (2001-05-01), None
patent: WO 01/326 33 (2001-05-01), None
patent: WO 01/74775 (2001-10-01), None
patent: WO 01/83 476 (2001-11-01), None
patent: WO 01/90 051 (2001-11-01), None
patent: WO 04/000 806 (2003-12-01), None
patent: WO 2005/09 9711 (2005-10-01), None
Moragues, et. al. Farmaco, Edizione Scientifica (1980), 35(11), 951-64.
G. C. Weir and J. L. Leahy, 1994, Pathogenesis of non-insulin dependent (Type II) diabetes mellitus, in Joslin's Diabetes Mellitus (Eds. C. R. Kahn and G. C. Weir), 13thEdition, 1994, Lea & Febiger, Malvern, PA, pp. 240-264.
H. E. Lebovitz, Oral antidiabetic agents, in Joslin's Diabetes Mellitus (Eds. C. R. Kahn and G. C. Weir), 13thEdition, 1994, Lea & Febiger, Malvern, PA, pp. 508-529.
C. J. Bailey, M. R. C. Path and R. C. TurnerN. Engl. J. Med1996, 334, 574-579.
G. L.Plosker and D. FauldsDrugs1999, 57, 409-438.
Y. Zambre, et. al.,Biochem. Pharmacol. 1999, 57, 1159-1164.
S. P. Fagan, et al,Surgery1998, 124, 254-258.
M. Norman, et al.,Ann. Surg. 2002, 235, 767-774.
T.A. Tirone, et al.,Pancreas2003, 26, e67-73.
M. Z. Strowski, et al.,Mol. Endocrinol. 2003, 17, 93-106.
K. Cejvan, D. H. Coy and S. EfendicDiabetes2003, 52, 1176-1181.
M. Z. Strowski, R. M. Parmar, A. D. Blake and J. M. SchaefferEndocrinology2000, 141, 111-117.
E. Näslund, et al.,Int. J. Obes. 1999, 23, 304-311.
J.-P. Gutzwiller, et al.,Gut1999, 44, 81-88.
J.-P. Gutzwiller, et al.,Am. J. Physiol. 1999, 276, R1541-1544.
M. D. Turton, et al.,Nature1996, 379, 69-72.
A. Flint, et al.,J. Clin. Invest. 1998, 101, 515-520.
M. B. Toft-Nielsen, et al.,Diabetes Care1999, 22, 1137-1143.
P. K. Cheikani, et al.,Am. J. Physiol. 2005, 288, R1695-R1706.
T. Miki, et al.,Diabetes2005, 54, 1056-1063.
L. Hansen, et al.,Am. J. Phys. 2000, 278, E1010-1018.
D. G. Burrin, et al.,Domest. Anim. Endocrinol. 2003, 24, 103-122.
K. V. Haderslev, et al.,Scand. J. Gastroenterol. 2002, 37, 392-398.
P. B. JeppesenJ. Nutr. 2003, 133, 3721-3724.
T. Talme, et al.,Clin. Exp. Immunol. 2001, 125, 71-79.
D. Ferone, et al.,Dig. Liver Dis. 2004, 36, S68-77.
C. E. Ghamrawy, et al.,Peptides1999, 20, 305-311.
J. P. Wolfe, et al.,J. Am. Chem. Soc. 1996, 118, 7215-7216.
J. P. Wolfe and S. L. BuchwaldTetrahedron Lett. 1997, 38, 6359-6362.
J. P. Wolfe, et al,Acc. Chem. Res. 1998, 31, 805-818.
B. H. Yang and S. L. BuchwaldJ. Organomet. Chem. 1999, 576, 125-146.
J. F. HartwigAngew. Chem. Int. Ed. 1998, 37, 2046-2067.
Q. Shen, et al.,Angew. Chem. Int. Ed. 2005, 44, 1371-1375.
Y.-Z. Kim, et al.,J. Med. Chem. 1994, 37, 3828-3833.
A. R. Katritzky and T. I. YousafCanad. J. Chem. 1986, 64, 2087-2093.
H. H. Wasserman and J. L. IvesJ. Am. Chem. Soc. 1976, 98, 7868-7869.
L. A. Paquette,Principles of Modern Heterocyclic Chemistry, 1968, W. A. Benjamin, Inc., New York (uracil synthesis pp. 313-315.
L. A. Paquette,Principles of Modern Heterocyclic Chemistry, 1968, W. A. Benjamin, Inc., New York ;pyrimidine synthesis pp. 313-316.
J. T. Bork, J. W. Lee and Y.-T. ChangQSAR Comb. Sci. 2004, 23, 245-260.
D. B. Harden, et al.,J. Org. Chem. 1988, 53, 4137-4140.
V. Oakes, et al,J. Chem. Soc., Abstracts1962, 4678-4685.
Z. Sui, et al.,Bioorg. Med. Chem. Lett. 2003, 13, 761-765.
H.-J. Hess, et al.,J. Med. Chem. 1968, 11, 130-136.
C. Flader, et al.,J. Med. Chem. 2000, 43, 3157-3167.
M. J. Ashton, et al.,J. Med Chem. 1994, 37, 1696-1703.
W. White, et al.,J. Med. Chem. 2000, 43, 4084-4097.
I. Kompis and A. WickHelv. Chim. Acta1977, 60, 3025-3034.
S. P. Dudek, et al., ChidseyJ. Am. Chem. Soc. 2001, 123, 8033-8038.
Moragues J., et al., Farmaco, Edizione Scientifica, Societa Chimica Italiana, Pavia, IT, vol. 35, No. 11, pp. 951-964 (1980), XP009032424.
Binggeli Alfred
Christ Andreas
Maerki Hans-Peter
Martin Rainer Eugen
Hoffmann-La Roche Inc.
Johnston George W.
Megerditchian Samuel H.
Murray Jeffrey H
Tramaloni Dennis P.
LandOfFree
Pyrimidine, quinazoline, pteridine and triazine derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyrimidine, quinazoline, pteridine and triazine derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrimidine, quinazoline, pteridine and triazine derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4167540